RATIONALE: Relaxin is a hormone that has been considered as a potential therapy for patients with fibrotic diseases. OBJECTIVES: To gauge the potential efficacy of relaxin-based therapies in idiopathic pulmonary fibrosis (IPF), we studied gene expression for relaxin/insulin-like family peptide receptor 1 (RXFP1) in IPF lungs and controls. METHODS: We analyzed gene expression data obtained from the Lung Tissue Research Consortium and correlated RXFP1 gene expression data with cross-sectional clinical and demographic data. We also employed ex vivo donor and IPF lung fibroblasts to test RXFP1 expression in vitro. We tested CGEN25009, a relaxin-like peptide, in lung fibroblasts and in bleomycin injury. MEASUREMENTS AND MAIN RESULTS: We found that RXFP1 is significantly decreased in IPF. In patients with IPF, the magnitude of RXFP1 gene expression correlated directly with diffusing capacity of the lung for carbon monoxide (P < 0.0001). Significantly less RXFP1 was detected in vitro in IPF fibroblasts than in donor controls. Transforming growth factor-β decreased RXFP1 in both donor and IPF lung fibroblasts. CGEN25009 was effective at decreasing bleomycin-induced, acid-soluble collagen deposition in vivo. The relaxin-like actions of CGEN25009 were abrogated by RXFP1 silencing in vitro, and, in comparison with donor lung fibroblasts, IPF lung fibroblasts exhibited decreased sensitivity to the relaxin-like effects of CGEN25009. CONCLUSIONS: IPF is characterized by the loss of RXFP1 expression. RXFP1 expression is directly associated with pulmonary function in patients with IPF. The relaxin-like effects of CGEN25009 in vitro are dependent on expression of RXFP1. Our data suggest that patients with IPF with the highest RXFP1 expression would be predicted to be most sensitive to relaxin-based therapies.
RATIONALE: Relaxin is a hormone that has been considered as a potential therapy for patients with fibrotic diseases. OBJECTIVES: To gauge the potential efficacy of relaxin-based therapies in idiopathic pulmonary fibrosis (IPF), we studied gene expression for relaxin/insulin-like family peptide receptor 1 (RXFP1) in IPF lungs and controls. METHODS: We analyzed gene expression data obtained from the Lung Tissue Research Consortium and correlated RXFP1 gene expression data with cross-sectional clinical and demographic data. We also employed ex vivo donor and IPF lung fibroblasts to test RXFP1 expression in vitro. We tested CGEN25009, a relaxin-like peptide, in lung fibroblasts and in bleomycin injury. MEASUREMENTS AND MAIN RESULTS: We found that RXFP1 is significantly decreased in IPF. In patients with IPF, the magnitude of RXFP1 gene expression correlated directly with diffusing capacity of the lung for carbon monoxide (P < 0.0001). Significantly less RXFP1 was detected in vitro in IPF fibroblasts than in donor controls. Transforming growth factor-β decreased RXFP1 in both donor and IPF lung fibroblasts. CGEN25009 was effective at decreasing bleomycin-induced, acid-soluble collagen deposition in vivo. The relaxin-like actions of CGEN25009 were abrogated by RXFP1 silencing in vitro, and, in comparison with donor lung fibroblasts, IPF lung fibroblasts exhibited decreased sensitivity to the relaxin-like effects of CGEN25009. CONCLUSIONS: IPF is characterized by the loss of RXFP1 expression. RXFP1 expression is directly associated with pulmonary function in patients with IPF. The relaxin-like effects of CGEN25009 in vitro are dependent on expression of RXFP1. Our data suggest that patients with IPF with the highest RXFP1 expression would be predicted to be most sensitive to relaxin-based therapies.
Authors: Roland M du Bois; Derek Weycker; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Alex Kartashov; Talmadge E King; Lisa Lancaster; Paul W Noble; Steven A Sahn; Michiel Thomeer; Dominique Valeyre; Athol U Wells Journal: Am J Respir Crit Care Med Date: 2011-09-22 Impact factor: 21.405
Authors: Carol A Feghali-Bostwick; Christopher G Tsai; Vincent G Valentine; Stephen Kantrow; Michael W Stoner; Joseph M Pilewski; Aneal Gadgil; M Patricia George; Kevin F Gibson; Augustine M K Choi; Naftali Kaminski; Yingze Zhang; Steven R Duncan Journal: J Immunol Date: 2007-08-15 Impact factor: 5.422
Authors: Edna D Lekgabe; Helen Kiriazis; Chongxin Zhao; Qi Xu; Xiao Lei Moore; Yidan Su; Ross A D Bathgate; Xiao-Jun Du; Chrishan S Samuel Journal: Hypertension Date: 2005-06-20 Impact factor: 10.190
Authors: Yasmina Bauer; John Tedrow; Simon de Bernard; Magdalena Birker-Robaczewska; Kevin F Gibson; Brenda Juan Guardela; Patrick Hess; Axel Klenk; Kathleen O Lindell; Sylvie Poirey; Bérengère Renault; Markus Rey; Edgar Weber; Oliver Nayler; Naftali Kaminski Journal: Am J Respir Cell Mol Biol Date: 2015-02 Impact factor: 6.914
Authors: Chrishan S Samuel; Chongxin Zhao; Ross A D Bathgate; Xiao-Jun DU; Roger J Summers; Edward P Amento; Lesley L Walker; Mary McBurnie; Ling Zhao; Geoffrey W Tregear Journal: Ann N Y Acad Sci Date: 2005-05 Impact factor: 5.691
Authors: John R Teerlink; Gad Cotter; Beth A Davison; G Michael Felker; Gerasimos Filippatos; Barry H Greenberg; Piotr Ponikowski; Elaine Unemori; Adriaan A Voors; Kirkwood F Adams; Maria I Dorobantu; Liliana R Grinfeld; Guillaume Jondeau; Alon Marmor; Josep Masip; Peter S Pang; Karl Werdan; Sam L Teichman; Angelo Trapani; Christopher A Bush; Rajnish Saini; Christoph Schumacher; Thomas M Severin; Marco Metra Journal: Lancet Date: 2012-11-07 Impact factor: 79.321
Authors: Chrishan S Samuel; Chongxin Zhao; Ross A D Bathgate; Courtney P Bond; Matthew D Burton; Laura J Parry; Roger J Summers; Mimi L K Tang; Edward P Amento; Geoffrey W Tregear Journal: FASEB J Date: 2002-11-01 Impact factor: 5.191
Authors: Ishanee Mookerjee; Tim D Hewitson; Michelle L Halls; Roger J Summers; Michael L Mathai; Ross A D Bathgate; Geoffrey W Tregear; Chrishan S Samuel Journal: FASEB J Date: 2008-12-10 Impact factor: 5.191
Authors: Anthony J Kanai; Elisa M Konieczko; Robert G Bennett; Chrishan S Samuel; Simon G Royce Journal: Mol Cell Endocrinol Date: 2019-02-14 Impact factor: 4.102
Authors: Jiangning Tan; John R Tedrow; Mehdi Nouraie; Justin A Dutta; David T Miller; Xiaoyun Li; Shibing Yu; Yanxia Chu; Brenda Juan-Guardela; Naftali Kaminski; Kritika Ramani; Partha S Biswas; Yingze Zhang; Daniel J Kass Journal: J Immunol Date: 2017-02-08 Impact factor: 5.422
Authors: Andrew J Haak; Enis Kostallari; Delphine Sicard; Giovanni Ligresti; Kyoung Moo Choi; Nunzia Caporarello; Dakota L Jones; Qi Tan; Jeffrey Meridew; Ana M Diaz Espinosa; Aja Aravamudhan; Jessica L Maiers; Rodney D Britt; Anja C Roden; Christina M Pabelick; Y S Prakash; Seyed Mehdi Nouraie; Xiaoyun Li; Yingze Zhang; Daniel J Kass; David Lagares; Andrew M Tager; Xaralabos Varelas; Vijay H Shah; Daniel J Tschumperlin Journal: Sci Transl Med Date: 2019-10-30 Impact factor: 17.956